Details

Autor(en) / Beteiligte

• Huguet, Françoise
• Cayuela, Jean‐Michel
• Cambier, Nathalie
• Carpentier, Nathalie
• Tindel, Malka
• Violet, Isabelle
• Zunic, Patricia
• Lascaux, Axelle
• Etienne, Gabriel

Titel

Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice

Ist Teil von

• British journal of haematology, 2019-12, Vol.187 (5), p.615-626

Ort / Verlag

England: Blackwell Publishing Ltd

Erscheinungsjahr

2019

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• Summary This observational, prospective study assessed, in a daily clinical practice, the molecular response, safety, quality of life (QoL) and treatment adherence in 183 patients with chronic myeloid leukaemia in chronic phase (CML‐CP), receiving nilotinib as first‐line treatment. Premature study termination before 24 months of follow‐up occurred in 61 patients (33·3%), and was essentially due to nilotinib treatment discontinuation (n = 53; 29%), motivated by treatment intolerance (n = 29; 15·8%) and inefficacy (n = 19; 10·4%). After 24 months of treatment, 112/122 patients (91·8%) had a molecular assessment, 95·5% of whom achieved a major molecular response (MMR), 32·1% achieved uMR4, defined as an undetectable molecular disease with 4‐log molecular response sensitivity (≥10 000 ABL1 transcripts). The Morisky Green Levine Medication Adherence Scale was completed by 94/122 patients (77·0%), and 89·4% of these patients obtained a satisfactory level of treatment adherence, defined as a score ≥3. Patients’ QoL was good at baseline and stable during the follow‐up period. The two most common nilotinib‐related adverse events (AEs) were pruritus (14·8%) and asthenia (13·7%). Seven patients (3·8%) experienced at least one cardiovascular ischaemic AE. This French nationwide cohort study provides relevant information in daily clinical practice indicating that nilotinib is a valuable first‐line treatment option for CML‐CP patients.